The predictors of long-term outcomes after targeted therapy for primary Aldosteronism

J Formos Med Assoc. 2023 Dec 14:S0929-6646(23)00471-0. doi: 10.1016/j.jfma.2023.11.005. Online ahead of print.ABSTRACTUnilateral primary aldosteronism is thought to be a surgically curable disease, and unilateral adrenalectomy is the mainstay treatment. The Primary Aldosteronism Surgical Outcome (PASO) consensus was developed to assess clinical and biochemical outcomes to standardize the classification of surgical outcomes. However, fewer than half of patients are cured of hypertension after adrenalectomy; therefore, preoperative patient counseling and evaluation might be necessary. Moreover, current studies show that genetic mutations and histopathology classification are associated with the treatment outcome. The Task Force of Taiwan PA recommends using a specific scoring system, including the PASO score and nomogram-based preoperative score, to predict the clinical outcome before adrenalectomy. Herein, we discuss the associations of current histopathological classification and specific somatic gene mutations with clinical outcomes after surgery.PMID:38097431 | DOI:10.1016/j.jfma.2023.11.005
Source: J Formos Med Assoc - Category: General Medicine Authors: Source Type: research